Disease · MONDO_0020546
Trials63
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.
1 to 20 of 63
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02913261 | Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation | Phase 3 | 310 | 2023-02-08 | Corticosteroid Refractory Acute Graft vs Host Disease | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00224874 | Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) | Phase 2 | 180 | 2010-04-09 | Graft vs Host Disease, Immune System Disorders | DENILEUKIN DIFTITOX, ETANERCEPT, MYCOPHENOLATE MOFETIL, PENTOSTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00189488 | Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | Phase 2 | 155 | 2014-09-15 | Graft Versus Host Disease, Hematologic Malignancies | PALIFERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT02806947 | A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501) | Phase 2 | 127 | 2019-12-17 | Acute GVHD | PREDNISONE, SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02133924 | Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease | Phase 2 | 76 | 2022-10-21 | Acute Graft Versus Host Disease | NATALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02953678 | A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) | Phase 2 | 71 | 2019-08-20 | Graft-versus-host Disease (GVHD) | METHYLPREDNISOLONE, PREDNISONE, RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02336230 | A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD) | Phase 3 | 55 | 2022-03-17 | Grade B aGVHD, Grade C aGVHD, Grade D aGVHD | REMESTEMCEL-L | Its record names the disease | ClinicalTrials.gov |
| NCT03491215 | Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease | Phase 1/2 | 45 | 2024-11-08 | Acute Graft Versus Host Disease | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00496340 | Phase II Trial of Pentostatin and Targeted Busulfan | Phase 2 | 42 | 2014-06-05 | Hematologic Malignancies | BUSULFAN, PENTOSTATIN, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01700036 | A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease | Phase 2 | 40 | 2018-01-05 | Graft vs Host Disease | .ALPHA.1-PROTEINASE INHIBITOR HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT02411084 | Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD | Phase 3 | 36 | 2020-01-30 | Graft vs Host Disease | BEGELOMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00726375 | The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease | Phase 3 | 34 | 2014-08-04 | Acute Graft Versus Host Disease | ETANERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT03763318 | A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD | Phase 1/2 | 30 | 2025-04-18 | Acute-graft-versus-host Disease, aGVHD, GVHD, GVHD, Acute | ITOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02524847 | Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease | Phase 3 | 29 | 2020-09-11 | Steroid Refractory Acute Graft Versus Host Disease | METHOXSALEN | Its record names the disease | ClinicalTrials.gov |
| NCT02176031 | Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD | Phase 2 | 21 | 2020-04-17 | Graft Versus Host Disease | NATALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02993783 | A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) | Phase 2 | 17 | 2019-05-24 | Allogeneic Hematopoietic Stem Cell Transplantation | VEDOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04934670 | A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) | Phase 3 | 12 | 2024-08-27 | Steroid-Refractory Acute Graft Versus Host Disease | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01485055 | Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease | Phase 2 | 11 | 2019-04-05 | Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease | BASILIXIMAB, INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02322190 | Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD | Phase 2 | 5 | 2020-03-12 | Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease | METHOXSALEN | Its record names the disease | ClinicalTrials.gov |
| NCT01453140 | In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus | Phase 1/2 | 3 | 2022-03-02 | Graft Versus Host Disease | ALDESLEUKIN, AZACITIDINE, CYCLOPHOSPHAMIDE, SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020546/trials